Merck KGaA makes changes to executive board
Moves follow departure of Elmar Schnee for personal reasons
Oschmann will be responsible for Merck Serono and Consumer Health Care divisions and personally assume the lead of the Merck Serono division on 1 January 2011.
Kai Beckmann will also become a member of the executive board and general partner of Merck KGaA from 1 April 2011. He will take the newly created executive board position of human resources.
Frank Stangenberg-Haverkamp, chairman of E Merck, thanked Schnee for his contributions to the firm’s success and wished him all the best for the future.
He said Oschmann was the ideal candidate to drive the internationalisation of Merck Serono and to advance the company’s pharmaceutical research and development.
Since 2009 Oschmann has been president of emerging markets for Merck & Co.
Stangen-Haverkamp said Beckmann proved his management skills in the IT business and when he was md in Singapore and Malaysia. Since 2007, he has pushed forward the modernisation and globalisation of Merck KGaA’s IT function in the role of chief technology officer.
You may also like
Research & Development
Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness
The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.